**Star News, Shengxiang Biology is about to release its 2023 annual report recently, and according to the performance express report released on February 28, the attributable net profit is 360.2 billion yuan, a year-on-year decrease of 814%。
Explanation of the operating performance and financial condition in the announcement of the performance report:
The company's total operating income and operating profit in 2023 decreased by more than 30% year-on-year, mainly due to changes in public health prevention and control policies at home and abroad, resulting in a sharp decline in demand for new crown nucleic acid detection reagents and instruments, and a decline in related business income. Owners' equity attributable to the parent decreased by 126%, mainly due to the company's full attention to the reasonable return on investment of shareholders and the implementation of multiple profit distributions, with a cumulative cash dividend of more than 400 million yuan in 2023.
The company adjusted and optimized its strategy in a timely manner according to the external environment and market changes, and gradually entered a period of development in its strategic layout in multiple tracks and fields, with endogenous drive and extension growth going hand in hand, showing strong growth potential. The company achieved operating income of 63,254 in the first three quarters of 2023340,000 yuan, operating income of 37,392 in the fourth quarter of 2023410,000 yuan, an increase of 8254%, and the development efficiency has been further accelerated. In 2023, the company's conventional reagent sales revenue will reach 78.4 billion yuan, a year-on-year increase of more than 150%, of which, the operating income of respiratory products exceeded 400 million yuan, a year-on-year increase of 680%, and further breakthroughs were made in HPV, blood screening, sequencing and other fields, and the early layout achieved remarkable results. The company continues to focus on the pain points of people's needs, the focus of industry development and the focus of national strategy, focusing on building a closed-loop of high-quality engineering advantages, a closed-loop of international advantages, and a closed-loop of government-finance, industry-university-research-application advantages, and continuously enhance the company's core competitiveness, ability to resist risks and go through the cycle. During the reporting period, the company's R&D and innovation capabilities, industrial transformation capabilities, overall ecosystem building capabilities, and global link capabilities continued to expand and upgrade, promoting the high-quality development of life science and technology empowerment.
The main business of Shengxiang Biology (688289) is to develop, produce and sell in vitro diagnostic reagents and instruments, and provide testing services.
A total of 2 institutions have rated the stock in the last 90 days,** 2 ratings.
The above content is compiled by **Star based on public information, generated by algorithms, and has nothing to do with the position of this site. **Star strives but does not guarantee the accuracy, completeness, validity, timeliness of all or part of the content of the information (including but not limited to text, **audio, data and charts), if there is any problem, please contact us. This article is a compilation of data and does not constitute any investment advice for you.